For example, upregulation of IL-12r or CTLA-4 (Figure 6) in both the HTB-1 and SiHa models may suggest a combination with an IL-12 or CTLA-4 modulating agent which may enhance the observed anti-tumor response. This evidence concerns the gene CTLA4 and neoplasm.